C07K 14/33
From clostridium
Official title: from Clostridium (G)
C07K14/33 (From clostridium) appears on 706 US grants and 967 published applications in this corpus.
Search patents in C07K- Granted patents
- 706
- Published applications
- 967
- Assignees
- 399
- Inventors
- 1,432
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 3 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 9 | 0 |
| 1997 | 12 | 0 |
| 1998 | 25 | 0 |
| 1999 | 14 | 0 |
| 2000 | 5 | 0 |
| 2001 | 18 | 5 |
| 2002 | 13 | 16 |
| 2003 | 12 | 29 |
| 2004 | 12 | 25 |
| 2005 | 9 | 19 |
| 2006 | 12 | 23 |
| 2007 | 18 | 30 |
| 2008 | 18 | 49 |
| 2009 | 14 | 51 |
| 2010 | 40 | 53 |
| 2011 | 36 | 37 |
| 2012 | 26 | 51 |
| 2013 | 37 | 47 |
| 2014 | 28 | 37 |
| 2015 | 29 | 50 |
| 2016 | 42 | 41 |
| 2017 | 27 | 27 |
| 2018 | 26 | 34 |
| 2019 | 20 | 38 |
| 2020 | 28 | 55 |
| 2021 | 33 | 42 |
| 2022 | 31 | 51 |
| 2023 | 24 | 34 |
| 2024 | 28 | 53 |
| 2025 | 19 | 34 |
| 2026 | 24 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Clostridium difficile antigens25 Aug 2026US 12,714,742 B2MicroPharm Limited
- Pegylated tetanus neurotoxins and treatment of hypotonia4 Aug 2026US 12,697,379 B2Snoretox Pty Ltd
- Recombinant fusion protein vaccine containing Clostridioides difficile FliC and FliD30 Jun 2026US 12,667,609 B2University of South Florida
- Proteins for the treatment of epithelial barrier function disorders23 Jun 2026US 12,661,383 B2Genevive, Inc.
- Evolved botulinum neurotoxins and uses thereof16 Jun 2026US 12,655,182 B2President and Fellows of Harvard College
- Proteins for the treatment of epithelial barrier function disorders24 Sep 2026US 2026/0284140 A1Genevive, Inc.
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284158 A1Allergan, Inc.
- Injection paradigm for administration of botulinum toxins24 Sep 2026US 2026/0284159 A1Allergan, Inc.
- Methods for the manufacture of proteolytically processed polypeptides24 Sep 2026US 2026/0286331 A1Ipsen Bioinnovation Limited
- Clostridium bacteria modified to assimilate several sugars simultaneously, preparation and uses thereof17 Sep 2026US 2026/0275271 A1Ifp Energies Nouvelles
Most cited
By later US patents
- Clostridial toxin derivatives able to modify peripheral sensory afferent functions318US 5,989,545 AMicrobiological Research Authority · 1999
- Therapeutic compounds comprised of anti-Fc receptor antibodies262US 5,837,243 AMedarex, Inc. · 1998
- Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies212US 5,922,845 AMedarex, Inc. · 1999
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998